CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2007-03-29): Dual HIV/HCV therapy tied to significant weight loss

Clinical

Dual HIV/HCV therapy tied to significant weight loss

Last Updated: 2007-03-29 15:11:04 -0400 (Reuters Health)

NEW YORK (Reuters Health) - The incidence of weight loss is greater in patients treated concomitantly for HIV and hepatitis C virus (HCV) infection than is the case for those with either infection alone, researchers report in the March 1st issue of the Journal of Acquired Immune Deficiency Syndromes.

Because of this, lead investigator Dr. Vincent Lo Re III told Reuters Health, "Health care providers managing coinfected patients should discuss the possibility of weight loss during hepatitis C therapy to prepare patients to cope with this adverse effect."

Dr. Lo Re of the University of Pennsylvania School of Medicine, Philadelphia, and colleagues note that clinical observations suggest that patients with HIV/HCV coinfection may lose body weight during dual therapy, but this has not been confirmed analytically.

To do so, the researchers retrospectively studied data on 192 patients with HIV/HCV who had received HAART and HCV therapy, 65 with HIV alone who had received HAART, and 64 with HCV alone who had received HCV therapy.

Follow-up of the HIV patients showed that at 18 months only two (3%) had clinically significant weight loss. However, as early as 12 months, weight loss was significant in 25 (39%) of the subjects with HCV and 48 (76%) of those with HIV/HCV. Patients who received more than two nucleoside reverse transcriptase inhibitors had a significantly increased risk of clinically significant weight loss (adjusted hazard ratio, 8.17).

Since weight loss can be extremely stigmatizing in the HIV population, Dr. Lo Re continued, "awareness of substantial weight loss during hepatitis C therapy could represent a barrier to coinfected patients' willingness to initiate hepatitis C treatment."

Moreover, "Since PEG-interferon alfa-2b and ribavirin are both dosed based on body weight, dose reduction of these medications may be required if body weight declines."

In concluding, he advised, "The use of oral appetite stimulants should be considered to counteract weight loss."

J Acquir Immune Defic Syndr 2007;44:344-350.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.